A recent review publication from the experts at the Dana-Farber Cancer Institute in Boston summarizes the most common adverse effects that occur during treatment.  The article was published in the journal, “Expert Opinion on Drug Safety”.

A summary box in the publication states:

  • There are several  effective  and  safe  options  for  the  treatment  of Waldenström macroglobulinemia although patients should be closely monitored  during  therapy  for  the  emergence  of  treatment-specific side effects.
  • Reduction in the  number  of  rituximab-bendamustine  treatment cycles may prevent toxicity without compromising disease outcomes.
  • The frequency of bortezomib dosing and the manner of administration can be altered to decrease the risk of peripheral neuropathy in patients with Waldenström macroglobulinemia.
  • Patients with Waldenström  macroglobulinemia  have  a  unique  side effect  profile  associated  with  rituximab,  including  increased  risk  of rituximab intolerance and IgM flares.
  • Ibrutinib is an effective treatment for Waldenström macroglobulinemia with a  medically  manageable  side  effect  profile  that  includes atrial  fibrillation  and  bleeding.  Newer  BTK  inhibitors  such  as  zanubrutinib and acalabrutinib show similar activity levels with differences in side-effect profile.

You can read or download the paper here.  It may be useful during discussions with your oncologist/hematologist.